Madrigal (MDGL) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Madrigal Pharmaceuticals (MDGL) reported a Q4 loss of $2.71 per share, which was better than the Zacks Consensus Estimate of a $4.12 loss. This is an improvement from the $5.68 loss per share reported a year ago.
February 26, 2025 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Madrigal Pharmaceuticals reported a Q4 loss of $2.71 per share, beating the Zacks Consensus Estimate of a $4.12 loss. This marks an improvement from the previous year's $5.68 loss per share.
The better-than-expected earnings report and improvement from the previous year are likely to positively impact MDGL's stock price in the short term. Investors may view the narrower loss as a sign of progress.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100